3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia, Lymphocytic, Chronic, B-Cell
9
Lymphoma, Mantle-Cell
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, Follicular
6
Lymphoma, B-Cell, Marginal Zone
6
Unspecified Adult Solid Tumor, Protocol Specific
5
Sezary Syndrome
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Large-Cell, Immunoblastic
5
Burkitt Lymphoma
5
Lymphoma, Large-Cell, Anaplastic
4
Immunoblastic Lymphadenopathy
4
Hodgkin Disease
4
Waldenstrom Macroglobulinemia
3
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Accelerated Phase
3
Leukemia
3
Blast Crisis
3
Sarcoma
2
Prostatic Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Multiple Myeloma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Interventions
Brentuximab Vedotin
7
dacetuzumab
4
Lenalidomide
3
Doxorubicin
3
Dexamethasone
3
spartalizumab
2
lintuzumab
2
fludarabine
2
Vincristine
2
Rituximab
2
Rifampin
2
Prednisone
2
Gemcitabine
2
Cyclophosphamide
2
tanespimycin
1
sabatolimab
1
pomalidomide
1
pirtobrutinib
1
fludarabine phosphate
1
ficlatuzumab
1
daratumumab
1
Vinblastine
1
Thiotepa
1
TAS4464
1
Sertraline
1
R-CHOP protocol
1
Pam2CSK4 acetate and ODN M362 combination
1
Midazolam
1
Melphalan
1
LCL161
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hematologic Diseases
×
tanespimycin
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled